Table 3 Summary of studies focusing on the efficacy of antiemetic therapy in patients receiving MEC
Author | Regimen (mg) | Acute CR (%) | Delayed CR (%) | Overall CR (%) | Chemotherapy |
|---|---|---|---|---|---|
Eisenberg et al. (2003) | Palo (0.25) | 63 | 54 | 46 | MEC |
Palo (0.75) | 57.1 | 56.6 | 47.1 | ||
Celio et al. (2011) | Palo (0.25) + Dex (8) day 1 | 88.6 | 68.7 | 67.5 | MEC |
Palo (0.25) + Dex (8) days 1-3 | 84.3 | 77.7 | 71.1 | ||
Tanioka et al. (2013) | Gra (1) + Dex (12) + Ap | 97.8 | 62.2 | 62.2 | CBDCA-based |
Gra (1) + Dex(12) | 95.7 | 52.2 | 52.2 | ||
Hesketh et al. (2016) | Gra (2) day1-3 + Dex (20) + Rol (180) | 91.7 | 82.3 | 80.2 | CBDCA-based |
Gra (2 mg) days1-3 + Dex (20 mg) | 88.0 | 65.6 | 64.6 | ||
Yahata et al. (2016) | Gra (1/4) + Dex (20) + Ap | 94.0 | 63.6 | 61.6 | CBDCA + PAC |
Gra (1/4) + Dex (20) | 90.4 | 49.3 | 47.3 | ||
Present study | Palo (0.75) + Dex (9.9) + Ap | 100 | 91.9 | 91.9 | CBDCA-based |